Latest On Trillium Therapeutics Inc (TRIL):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-11-17 04:55 EST | News | Trillium Therapeutics gains quickly after Nasdaq delisting notice on Pfizer deal | N/A |  |
| 2021-11-17 04:53 EST | News | Trillium Therapeutics gets Canada, HSR approval for sale to Pfizer | N/A | |
| 2021-08-28 12:21 EST | News | Trillium, Triple-S lead weekly healthcare gainers amid acquisitions; Cassava Sciences lags | N/A | |
| 2021-08-23 16:30 EST | News | Trillium Therapeutics stock triples after acquisition by Pfizer for $2.3B | N/A | |
| 2021-08-13 22:14 EST | News | Trillium Therapeutics EPS misses by $0.04 | N/A | |
| 2021-08-09 16:11 EST | News | Trillium gets dosing underway in early-stage acute myeloid leukemia study | N/A | |
| 2021-07-22 04:26 EST | News | Trillium Therapeutics to join Russell 2000 and 3000 Index | N/A | |
| 2021-07-22 04:24 EST | News | Dosing underway in Trillium Therapeutics' mid-stage TTI-621 comb study in leiomyosarcoma | N/A | |
| 2021-07-22 04:23 EST | News | Trillium Therapeutics adds Catherine Mackey to its board of directors | N/A | |
| 2021-07-22 04:19 EST | News | Dosing underway in Trillium Therapeutics' Phase 1b/2 TTI-622 combo study in acute myeloid leukemia | N/A | |
| 2021-04-14 15:02 EST | News | Organigram cut on profitability concerns, Novocure downgraded despite positive news, and more in today's analyst action | N/A | |
| 2021-04-14 15:01 EST | News | Trillium Therapeutics' CD47 Lead Evokes Pfizer's Interest | N/A | |
| 2021-01-19 04:05 EST | News | Trillium Therapeutics: A Potentially Undervalued CD47 Player | N/A | |
| 2020-12-11 12:52 EST | News | Trillium Therapeutics (TRIL) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow | N/A | |
| 2020-12-08 13:24 EST | News | Trillium ticks lower on underwhelming data from TT1-622/621 in hematological malignancies trials | N/A | |
| 2020-11-26 21:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-18 05:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 21:34 EST | News | Trillium Therapeutics reports 9M results | N/A | |
| 2020-11-14 13:00 EST | News | Trillium Therapeutics: Investors To See Further Upside Via CD47 Focus | N/A | |
| 2020-11-08 01:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-12 17:13 EST | News | Trillium started at Street-high $28 price target by new bull Evercore | N/A | |
| 2020-10-05 18:22 EST | News | Trillium Therapeutics secures two new patents in U.S. | N/A | |
| 2020-09-26 14:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-11 12:39 EST | News | Trillium prices equity offering at $13 | N/A | |
| 2020-09-10 07:09 EST | News | Trillium launches 8.5M-share stock offering | N/A | |
| 2020-09-09 01:44 EST | News | Encouraging data on blood cancer candidates lifts Trillium, up 40% | N/A | |
| 2020-08-14 10:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 01:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-13 02:13 EST | News | Trillium Therapeutics reports 1H results | N/A | |
| 2020-08-06 14:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 09:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 13:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 18:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 17:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 13:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 05:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 06:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-29 21:09 EST | News | Trillium Therapeutics (TRIL) Investor Presentation - Slideshow | N/A | |
| 2020-05-27 06:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 02:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-20 17:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-18 05:21 EST | News | Trillium Therapeutics EPS misses by $0.97 | N/A | |
| 2020-05-06 06:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 06:00 EST | Financials | Company financials have been released. | Neutral | |
About Trillium Therapeutics Inc (TRIL):
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
General
- Name Trillium Therapeutics Inc
- Symbol TRIL
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:30
- Last Split Date2014-11-20
- Fiscal Year EndDecember
- IPO Date2005-03-23
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://trilliumtherapeutics.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 6772.95
- Price/Book (Most Recent Quarter) 7.17
- Enterprise Value Revenue 7847.49
View More
Financials
- Most Recent Quarter 2020-09-30
- Operating Margin -43411%
- Return on Assets -19%
- Return on Equity -189%
- Revenue 115000
- Earnings Per Share -$2.55
- Revenue Per Share $0
- Gross Profit 124000
- Quarterly Earnings Growth 360%
View More
Highlights
- Market Capitalization 1.09 billion
- Analyst Target Price $11.02
- Book Value Per Share $1.64
View More
Share Statistics
- Shares Outstanding 100.71 million
- Shares Float 83.86 million
- % Held by Insiders <1%
- % Held by Institutions 68.87%
- Shares Short 8.22 million
- Shares Short Prior Month 8.9 million
- Short Ratio 5.52
- Short % of Float 8%
- Short % of Shares Outstanding 8%
View More
Technicals
- Beta 1.96
- 52 Week High $20.96
- 52 Week Low $3.01
- 50 Day Moving Average 12.12
- 200 Day Moving Average 13.6
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Trillium Therapeutics Inc (TRIL) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Trillium Therapeutics Inc (TRIL) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-16 | $N/A | -$0.55 | -$0.17 | -226.33% |
| 2020-06-30 | 2020-08-12 | $N/A | -$0.57 | -$0.12 | -392.51% |
| 2020-03-31 | 2020-05-15 | $N/A | -$1.07 | -$0.10 | -933.24% |
| 2019-12-31 | 2020-03-10 | $-3213 | -$0.42 | -$0.22 | -92.94% |
| 2019-09-30 | 2019-11-14 | $98935.13 | -$0.35 | -$0.33 | -4.77% |
| 2019-06-30 | 2019-08-13 | $25981.97 | -$0.12 | -$0.40 | 69.84% |
| 2019-03-31 | 2019-05-13 | $N/A | -$0.45 | -$0.40 | -12.19% |
| 2018-12-31 | 2019-03-11 | $N/A | -$0.43 | -$0.65 | 35.03% |
| 2018-09-30 | 2018-11-14 | $N/A | -$0.69 | -$0.68 | -1.49% |
| 2018-06-30 | 2018-08-08 | $N/A | -$0.71 | -$0.65 | -9.29% |
| 2018-03-31 | 2018-05-11 | $N/A | -$0.51 | -$0.64 | 20.61% |
| 2017-12-31 | 2018-03-09 | $N/A | -$0.66 | -$0.73 | 10.12% |
| 2017-09-30 | 2017-11-10 | $N/A | -$0.77 | -$0.85 | 8.88% |
| 2017-06-30 | 2017-08-11 | $N/A | -$1.05 | -$1.08 | 3.27% |
| 2017-03-31 | 2017-05-12 | $N/A | -$1.06 | -$0.92 | -15.64% |
| 2016-12-31 | 2017-03-10 | $N/A | -$0.85 | -$0.92 | 7.63% |
| 2016-09-30 | 2016-11-10 | $N/A | -$0.75 | -$0.77 | 3.02% |
| 2016-06-30 | 2016-08-12 | $N/A | -$0.75 | -$0.74 | -1.52% |
| 2016-03-31 | 2016-05-13 | $N/A | -$0.71 | -$0.67 | -5.65% |
| 2015-12-31 | 2016-03-09 | $N/A | -$0.29 | -$0.82 | 64.98% |
| 2015-09-30 | 2015-11-10 | $N/A | -$0.21 | -$1.05 | 80% |
| 2015-06-30 | 2015-08-11 | $N/A | -$0.80 | -$0.75 | -6.67% |
| 2015-03-31 | 2015-04-01 | $N/A | -$0.98 | -$0.60 | -63.33% |
| 2014-12-31 | 2015-03-22 | $N/A | -$0.97 | -$0.68 | -42.65% |
| 2014-09-30 | 2014-11-13 | $N/A | -$0.55 | ||
| 2014-06-30 | 2014-08-12 | $N/A | -$0.89 | ||
| 2014-03-31 | 2014-05-20 | $N/A | -$0.45 | ||
| 2013-09-30 | 2013-11-01 | $N/A | -$0.88 | ||
| 2013-06-30 | 2013-08-28 | $N/A | -$0.98 | ||
| 2013-03-31 | 2013-05-24 | $N/A | -$0.48 | ||
| 2012-12-31 | 2012-12-31 | $N/A | -$0.02 | ||
| 2012-09-30 | 2012-09-30 | $N/A | -$0.65 | ||
| 2012-06-30 | 2012-06-30 | $N/A | -$0.50 | ||
| 2012-03-31 | 2012-03-31 | $N/A | -$0.53 | ||
| 2011-12-31 | 2011-12-31 | -$2.34 | |||
| 2011-09-30 | 2011-09-30 | -$1.05 | |||
| 2011-06-30 | 2011-06-30 | -$1.16 | |||
| 2011-03-31 | 2011-03-31 | -$0.79 | |||
| 2010-12-31 | 2010-12-31 | -$1.64 | |||
| 2010-09-30 | 2010-09-30 | -$2.89 | |||
| 2010-06-30 | 2010-06-30 | -$2.92 | |||
| 2010-03-31 | 2010-03-31 | -$2.44 | |||
| 2009-12-31 | 2009-12-31 | -$2.84 | |||
| 2009-09-30 | 2009-09-30 | -$3.07 | |||
| 2009-06-30 | 2009-06-30 | -$1.91 | |||
| 2009-03-31 | 2009-03-31 | -$1.60 | |||
| 2008-12-31 | 2008-12-31 | -$2.76 | |||
| 2008-09-30 | 2008-09-30 | -$3.99 | |||
| 2008-06-30 | 2008-06-30 | -$4.41 | |||
| 2008-03-31 | 2008-03-31 | -$3.91 | |||
| 2007-12-31 | 2007-12-31 | -$6.12 | |||
| 2007-09-30 | 2007-09-30 | -$5.57 | |||
| 2007-06-30 | 2007-06-30 | -$3.24 | |||
| 2007-03-31 | 2007-03-31 | -$5.28 |
Trillium Therapeutics Inc (TRIL) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 4.37 million | 4.73 million | 6.28 million |
| Income Before Tax | N/A | N/A | -70.05 million | -18.66 million | -9.5 million |
| Selling General Administrative | N/A | N/A | 1.5 million | 2.89 million | 1.04 million |
| Gross Profit | N/A | N/A | N/A | -3213 | 98935.13 |
| Ebit | N/A | N/A | -69.8 million | -7.62 million | -7.22 million |
| Operating Income | N/A | N/A | -5.87 million | -7.62 million | -7.22 million |
| Income Tax Expense | 9000 | 28000 | N/A | 3328 | 12838.91 |
| Total Revenue | N/A | N/A | N/A | -3213 | 98935.13 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | -64.55 million | -11.04 million | -2.28 million |
| Net Income From Continuing Operations | N/A | N/A | -70.07 million | -18.67 million | -9.51 million |
| Net Income Applicable to Common Shares | -50.53 million | -52.41 million | N/A | -18.67 million | -9.51 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -3.95 million | 7.21 million | 6.75 million |
| Change to Liabilities | 3.38 million | -12.24 million | N/A | 2.49 million | 718978.93 |
| Total Cash Flow from Investing Activities | 2.88 million | -45.93 million | N/A | 7.12 million | 6.75 million |
| Net Borrowings | -73000 | -65000 | N/A | -72146 | -95914.21 |
| Total Cash Flow from Financial Activities | N/A | N/A | 119.74 million | -756984 | -95914.21 |
| Change to Operating Activities | -2.04 million | 401000 | N/A | 317094 | 706140.02 |
| Change in Cash | N/A | N/A | 108.44 million | 2.75 million | 1.47 million |
| Total Cash from Operating Activities | -4.13 million | -6.25 million | -7.15 million | -4.15 million | -5.26 million |
| Depreciation | N/A | N/A | 199000 | 168505 | 641190.24 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | 140925 | -274148.48 |
| Other Cash Flow from Financing Activities | N/A | 7.22 million | N/A | -535318 | N/A |
| Change to Net Income | 44.99 million | 57.68 million | N/A | 11.4 million | 2.47 million |
| Capital Expenditures | N/A | N/A | N/A | 91161 | 3020.92 |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 66.43 million | 55.79 million | 25.58 million | 11.85 million |
| Total Stockholder Equity | N/A | 68.74 million | 84.12 million | -24.83 million | -6.6 million |
| Other Current Liabilities | 233000 | 1.14 million | 934000 | 773000 | 597386.9 |
| Total Assets | N/A | 135.16 million | 139.9 million | 25.41 million | 30.47 million |
| Common Stock | 494.2 million | 319.18 million | N/A | 150.94 million | 135.54 million |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -364 million | -313.48 million | -261.07 million | -191 million | -161.95 million |
| Other Liabilities | 99.67 million | 55.69 million | N/A | 12.05 million | 1.22 million |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Cash | N/A | 72.87 million | 123.02 million | 14.58 million | 12.32 million |
| Total Current Liabilities | 13.2 million | 10.73 million | 22.77 million | 13.53 million | 10.63 million |
| Other Stockholder Equity | -7.43 million | -7.43 million | N/A | -7.43 million | N/A |
| Property, Plant & Equipment | 1.52 million | 1.72 million | N/A | 2.12 million | 2.2 million |
| Total Current Assets | 296.28 million | 133.44 million | 137.99 million | 23.29 million | 28.27 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 164.75 million | 45.58 million | N/A | -24.83 million | -6.6 million |
| Short Term Investments | N/A | 57.97 million | 12.04 million | 8.08 million | 15.04 million |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 12.97 million | N/A | N/A | 12.75 million | 10.03 million |
Trillium Therapeutics Inc (TRIL) Chart:
Trillium Therapeutics Inc (TRIL) News:
Below you will find a list of latest news for Trillium Therapeutics Inc (TRIL) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Trillium Therapeutics Inc (TRIL) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Trillium Therapeutics Inc (TRIL) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002648/0001062993-20-002648-index.htm |
| 2018-05-24 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1616212/000000000018016193/0000000000-18-016193-index.htm |
| 2020-05-06 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1616212/000000000020003968/0000000000-20-003968-index.htm |
| 2018-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000081229518000021/0000812295-18-000021-index.htm |
| 2018-12-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000089542118000638/0000895421-18-000638-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000089542119000072/0000895421-19-000072-index.htm |
| 2019-12-31 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000089542119000687/0000895421-19-000687-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000089542120000174/0000895421-20-000174-index.htm |
| 2020-05-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000089542120000350/0000895421-20-000350-index.htm |
| 2017-12-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000090266417004518/0000902664-17-004518-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000090266419001098/0000902664-19-001098-index.htm |
| 2019-03-04 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000090266419001363/0000902664-19-001363-index.htm |
| 2020-01-21 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000090266420000305/0000902664-20-000305-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000090266420001126/0000902664-20-001126-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000092963819000264/0000929638-19-000264-index.htm |
| 2017-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299317004778/0001062993-17-004778-index.htm |
| 2017-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299317004785/0001062993-17-004785-index.htm |
| 2017-11-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299317004978/0001062993-17-004978-index.htm |
| 2017-11-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299317005004/0001062993-17-005004-index.htm |
| 2017-11-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299317005038/0001062993-17-005038-index.htm |
| 2017-12-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299317005136/0001062993-17-005136-index.htm |
| 2017-12-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299317005224/0001062993-17-005224-index.htm |
| 2017-12-12 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1616212/000106299317005233/0001062993-17-005233-index.htm |
| 2017-12-15 | F-10 | Registration Statement for Securities of certain Canadian Issuers. | https://www.sec.gov/Archives/edgar/data/1616212/000106299317005267/0001062993-17-005267-index.htm |
| 2017-12-15 | F-X | Appointment of Agent for Service of Process and Undertaking | https://www.sec.gov/Archives/edgar/data/1616212/000106299317005269/0001062993-17-005269-index.htm |
| 2018-01-08 | F-10/A | Registration Statement for Securities of certain Canadian Issuers. | https://www.sec.gov/Archives/edgar/data/1616212/000106299318000048/0001062993-18-000048-index.htm |
| 2018-01-08 | F-10/A | Registration Statement for Securities of certain Canadian Issuers. | https://www.sec.gov/Archives/edgar/data/1616212/000106299318000073/0001062993-18-000073-index.htm |
| 2018-01-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318000190/0001062993-18-000190-index.htm |
| 2018-02-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318000516/0001062993-18-000516-index.htm |
| 2018-03-09 | 40-F | Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318001130/0001062993-18-001130-index.htm |
| 2018-03-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318001131/0001062993-18-001131-index.htm |
| 2018-03-13 | 40-F/A | Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318001177/0001062993-18-001177-index.htm |
| 2018-03-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318001269/0001062993-18-001269-index.htm |
| 2018-04-04 | 40-F/A | Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318001503/0001062993-18-001503-index.htm |
| 2018-04-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318001561/0001062993-18-001561-index.htm |
| 2018-04-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318001603/0001062993-18-001603-index.htm |
| 2018-04-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318001710/0001062993-18-001710-index.htm |
| 2018-05-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002096/0001062993-18-002096-index.htm |
| 2018-05-16 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002283/0001062993-18-002283-index.htm |
| 2018-05-29 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002413/0001062993-18-002413-index.htm |
| 2018-06-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002483/0001062993-18-002483-index.htm |
| 2018-06-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002504/0001062993-18-002504-index.htm |
| 2018-06-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002605/0001062993-18-002605-index.htm |
| 2018-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002617/0001062993-18-002617-index.htm |
| 2018-06-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002629/0001062993-18-002629-index.htm |
| 2018-06-20 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002666/0001062993-18-002666-index.htm |
| 2018-06-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002667/0001062993-18-002667-index.htm |
| 2018-06-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002668/0001062993-18-002668-index.htm |
| 2018-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318002711/0001062993-18-002711-index.htm |
| 2018-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318003174/0001062993-18-003174-index.htm |
| 2018-08-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318003586/0001062993-18-003586-index.htm |
| 2018-09-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318003714/0001062993-18-003714-index.htm |
| 2018-09-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318003860/0001062993-18-003860-index.htm |
| 2018-09-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318003874/0001062993-18-003874-index.htm |
| 2018-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318004585/0001062993-18-004585-index.htm |
| 2018-12-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299318004870/0001062993-18-004870-index.htm |
| 2019-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001035/0001062993-19-001035-index.htm |
| 2019-02-22 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001039/0001062993-19-001039-index.htm |
| 2019-02-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001041/0001062993-19-001041-index.htm |
| 2019-02-25 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001062/0001062993-19-001062-index.htm |
| 2019-02-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001064/0001062993-19-001064-index.htm |
| 2019-03-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001215/0001062993-19-001215-index.htm |
| 2019-03-11 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001231/0001062993-19-001231-index.htm |
| 2019-03-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001234/0001062993-19-001234-index.htm |
| 2019-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001424/0001062993-19-001424-index.htm |
| 2019-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001508/0001062993-19-001508-index.htm |
| 2019-04-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001598/0001062993-19-001598-index.htm |
| 2019-04-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001650/0001062993-19-001650-index.htm |
| 2019-04-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001695/0001062993-19-001695-index.htm |
| 2019-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319001916/0001062993-19-001916-index.htm |
| 2019-05-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319002133/0001062993-19-002133-index.htm |
| 2019-05-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319002356/0001062993-19-002356-index.htm |
| 2019-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319002766/0001062993-19-002766-index.htm |
| 2019-07-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319002999/0001062993-19-002999-index.htm |
| 2019-08-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319003319/0001062993-19-003319-index.htm |
| 2019-09-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319003608/0001062993-19-003608-index.htm |
| 2019-09-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319003735/0001062993-19-003735-index.htm |
| 2019-10-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319003841/0001062993-19-003841-index.htm |
| 2019-10-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319003977/0001062993-19-003977-index.htm |
| 2019-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319004170/0001062993-19-004170-index.htm |
| 2019-11-14 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1616212/000106299319004391/0001062993-19-004391-index.htm |
| 2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299319004393/0001062993-19-004393-index.htm |
| 2020-01-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320000039/0001062993-20-000039-index.htm |
| 2020-01-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320000186/0001062993-20-000186-index.htm |
| 2020-01-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320000269/0001062993-20-000269-index.htm |
| 2020-01-23 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320000272/0001062993-20-000272-index.htm |
| 2020-01-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320000274/0001062993-20-000274-index.htm |
| 2020-01-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320000281/0001062993-20-000281-index.htm |
| 2020-01-23 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320000283/0001062993-20-000283-index.htm |
| 2020-01-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320000363/0001062993-20-000363-index.htm |
| 2020-02-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320000498/0001062993-20-000498-index.htm |
| 2020-02-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320001200/0001062993-20-001200-index.htm |
| 2020-03-10 | 40-F | Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320001304/0001062993-20-001304-index.htm |
| 2020-03-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320001306/0001062993-20-001306-index.htm |
| 2020-04-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320001697/0001062993-20-001697-index.htm |
| 2020-04-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320001910/0001062993-20-001910-index.htm |
| 2020-04-23 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1616212/000106299320001914/0001062993-20-001914-index.htm |
| 2020-04-30 | F-3/A | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002043/0001062993-20-002043-index.htm |
| 2020-04-30 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002047/0001062993-20-002047-index.htm |
| 2020-05-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002136/0001062993-20-002136-index.htm |
| 2020-05-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002138/0001062993-20-002138-index.htm |
| 2020-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002140/0001062993-20-002140-index.htm |
| 2020-05-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002296/0001062993-20-002296-index.htm |
| 2020-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002485/0001062993-20-002485-index.htm |
| 2020-05-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002587/0001062993-20-002587-index.htm |
| 2020-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320002648/0001062993-20-002648-index.htm |
| 2020-07-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320003139/0001062993-20-003139-index.htm |
| 2020-07-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320003562/0001062993-20-003562-index.htm |
| 2020-08-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320003831/0001062993-20-003831-index.htm |
| 2020-09-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004386/0001062993-20-004386-index.htm |
| 2020-09-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004396/0001062993-20-004396-index.htm |
| 2020-09-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004398/0001062993-20-004398-index.htm |
| 2020-09-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004410/0001062993-20-004410-index.htm |
| 2020-09-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004414/0001062993-20-004414-index.htm |
| 2020-09-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004454/0001062993-20-004454-index.htm |
| 2020-09-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004468/0001062993-20-004468-index.htm |
| 2020-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004525/0001062993-20-004525-index.htm |
| 2020-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004560/0001062993-20-004560-index.htm |
| 2020-10-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320004787/0001062993-20-004787-index.htm |
| 2020-11-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1616212/000106299320005329/0001062993-20-005329-index.htm |
| 2017-12-05 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1616212/000107261317000621/0001072613-17-000621-index.htm |
| 2019-03-04 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1616212/000107261319000117/0001072613-19-000117-index.htm |
| 2020-02-04 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1616212/000107261320000019/0001072613-20-000019-index.htm |
| 2020-01-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000110465920005549/0001104659-20-005549-index.htm |
| 2018-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000114420418007958/0001144204-18-007958-index.htm |
| 2020-02-03 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000119312520022982/0001193125-20-022982-index.htm |
| 2020-02-03 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000121390020002392/0001213900-20-002392-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000121465920001477/0001214659-20-001477-index.htm |
| 2018-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000153526418000034/0001535264-18-000034-index.htm |
| 2019-01-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1616212/000153526419000004/0001535264-19-000004-index.htm |
| 2018-01-08 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1616212/999999999518000073/9999999995-18-000073-index.htm |
| 2018-05-31 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1616212/999999999518001393/9999999995-18-001393-index.htm |
| 2020-05-04 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1616212/999999999520001027/9999999995-20-001027-index.htm |